AzTrials
AzTrials

Stage IV (Metastatic) Breast CancerPhase 2HER2-SignalNCT04901299

Fulvestrant + Neratinib In Breast Cancer

A Phase 2 study testing NERATINIB and FULVESTRANT in people with Stage IV (Metastatic) Breast Cancer and Metastatic Breast Cancer, run by Massachusetts General Hospital at 2 sites in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative breast cancer. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
NERATINIB and FULVESTRANT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
2 sitesUnited States
Study dates
Jul 2023to 1 Jul 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult (≥ 18 years of age).
  • Histologically or cytologically confirmed stage IV (metastatic) breast cancer. PI approval is needed for patients who do not have source documentation of histologically confirmed stage IV (metastatic) breast cancer, but otherwise have known metastatic breast cancer.
  • Participants must have biopsy proven HR+, i.e ER positive (ER+) and/or PR positive (PR+), HER2 non-amplified (negative), invasive breast cancer. ER, PR, and HER2 positivity would be determined per institutional (local) testing, with HR+/HER2 nonamplified (negative) status for this trial determined as per 2020 ASCO/CAP guidelines, in a biopsy/surgical specimen analyzed for ER/PR/HER2. Patients with "ER or PR low positive" (<10%) as per updated ASCO/CAP 2020 guidelines can be considered.Confirmation of adequate (15-20 unstained slides cut at 5-10 μm or 1 block) archival tissue (primary or metastatic) required before study entry. If adequate tissue not available, PI approval is required prior to study entry.
  • Previously treated with no more than three prior chemotherapy regimens (no limit on prior endocrine-based regimens (including CDK4/6i and PI3K pathway inhibitors) or immunotherapy). In patients with disease recurrence during/within 12 months of (neo)adjuvant therapy, the (neo)adjuvant therapy would count as one prior regimen for this criterion. Radiation therapy or local therapy/surgery would not count as prior regimen for this criterion. Patient who discontinued chemotherapy during/after only one cycle and/or due to adverse effects without disease progression would not count the treatment/regimen as prior regimen for this criterion. Antibody drug conjugate and PARP inhibitor treatment would count as chemotherapy regimen for this criterion.
  • Hyperactive HER2 signaling activity based on results from the CELsignia test (separate pre-screening test).
  • Postmenopausal women with locally advanced or metastatic BC. Patients must be postmenopausal women as defined by one of the following:
Show all 23Show fewer
  • Women > 60 years OR
  • Women ≤ 60 years, and any one of the following:
  • LH and FSH level in the postmenopausal range according to institutional standards
  • s/p post bilateral surgical oophorectomy
  • Premenopausal/perimenopausal women on gonadotropin-releasing hormone agonist (to be continued during study) and estradiol level in the postmenopausal range according to institutional standards.
  • ECOG performance status = 0-2
  • Measurable disease as per RECIST Version 1.1.
  • Ability to understand and the willingness to undergo tissue biopsy for HER2 testing (CELsignia test). Patient has signed the Informed Consent (ICF) prior to any screening procedures being performed and is able to comply with protocol requirements.
  • At least 2 weeks beyond treatment (chemotherapy, targeted therapy, immunotherapy, and/or radiation therapy) or major surgery and recovered from all acute toxicities prior to randomization. (adverse events from prior anti-cancer agents need to be grade 1 or lower; grade 2 alopecia or peripheral neuropathy is permitted).
  • Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:
  • Absolute neutrophil count ≥ 1.5 × 109/L
  • Platelets ≥ 75 × 109/L
  • Hemoglobin ≥ 9.0 g/dL (transfusion permitted)
  • INR ≤1.5
  • GFR or creatinine clearance ≥50 mL/min (either permitted)
  • In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN. If the patient has liver metastases, ALT and AST <5 x ULN.
  • Total bilirubin ≤1.5.0 x ULN, or direct bilirubin ≤3 x ULN in patients with well documented Gilbert's Syndrome.

Who cannot join

  • Participants who have received prior neratinib or any anti-HER2 therapy for metastatic disease will not be eligible. Participants who have received prior fulvestrant (or any other endocrine therapy) will be eligible. Patients with known HER2 activating mutations (either plasma and/or tissue-based genotyping) will not be eligible.
  • Participants with increasing/progressive CNS metastatic disease. Patients with asymptomatic or stable CNS metastasis are eligible, provided metastasis radiologically non-progressing for at least two weeks, and patient is not actively taking steroids (more than 20 mg of prednisone or equivalent dose).
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:
  • History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry.
  • Known LVEF <50% (by ECHO or MUGA) and/or known documented cardiomyopathy.
Show all 16Show fewer
  • History of cardiac failure, significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following:
  • Known risk to prolong the QT interval or induce Torsade's de Pointes.
  • On screening, QTcF >470 screening ECG.
  • HIV-positive participants on combination antiretroviral therapy are ineligible. These participants are at increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
  • Pregnant women are excluded from this study because the safety of study medications is not established in pregnant women.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, or fertile men, unless they are using highly effective methods of contraception throughout the study and after study drug discontinuation (till seven months in women and four months in males, post-study). Male patient should not donate sperm while on treatment and up to 6 months after last dose. Women are considered postmenopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. Highly effective contraception methods include:
  • Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.
  • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception.
  • In case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Note: While oral contraceptives are allowed, they should be used in conjunction with a barrier method of contraception due to unknown effect of drug-drug interaction.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

  • Massachusetts General Hospital

    Boston, Massachusetts, 02115

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37232

Other trials in United States

About this study

Official title: An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function

This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative breast cancer.

  • This research study involves the study drug Neratinib
  • The standard of care drug Fulvestrant
Read the detailed description
  • The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
  • This research study involves the study drug Neratinib
  • The standard of care drug Fulvestrant
  • It is expected that about 25 people will take part in this research study.
  • This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
  • The U.S. Food and Drug Administration (FDA) has not approved Neratinib for this specific disease but it has been approved for other uses.
  • The FDA has approved Fulvestrant as a treatment option for this disease. Fulvestrant is a standard of care drug that will be administered.
Being tested
NERATINIB, FULVESTRANT
Keywords
stage IV (metastatic) breast cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Medical subject headings
Neoplasm Metastasis, Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NERATINIBDrug

    Also called Nerlynx

    Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol

  • FULVESTRANTDrug

    Also called Faslodex

    Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol

Study groups in NCT04901299
Study groupRoleWhat they receive
NERATINIB + FULVESTRANTExperimentalAfter the screening procedures confirm participation in the research study. - Each Cycle = 28 days * Neratinib (oral, once daily) * Fulvestrant, injection, on 2 days for cycle 1, then one time per cycle thereafter
Receives: Drug: NERATINIB; Drug: FULVESTRANT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective response rates (ORR)

    ORR is defined as the proportion of patients with a confirmed CR or PR per Investigator's assessment per RECIST v1.1

    Measured: Up to 33 Months

Secondary outcomes (10)

  1. Time-to-Tumor Response (TTR)

    defined for patients with confirmed objective response (CR or PR) as the time from the first dose of study treatment to the first documentation of objective tumor response

    Measured: Up to 33 Months

  2. Cumulative Objective Response Incidence

    defined as the cumulative proportion of patients with an objective response (CR or PR) after study treatment. The cumulative number of patients with an OR will be determined at the end of each time period and the cumulative incidence will then be calculated.

    Measured: Up to 33 Months

  3. Duration of response (DOR)

    is defined for patients with confirmed objective response (CR or PR) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. DR will be analyzed using Kaplan-Meier methods and descriptive statistics.

    Measured: Up to 33 Months

  4. Progression-Free Survival (PFS)

    defined as the time from the first dose of study treatment to the date of progression by RECIST v1.1 or death due to any cause, whichever occurs first. PFS will be analyzed using Kaplan-Meier methods and descriptive statistics.

    Measured: Up to 33 Months

  5. Overall survival (OS)

    defined as the time from the first dose of study treatment to the date of death. OS will be analyzed using Kaplan-Meier methods and descriptive statistics.

    Measured: Up to 33 Months

  6. Number of Participants with Treatment Related Adverse Events as Assessed NCI CTCAE (version 5.0)

    NCI CTCAE (version 5.0) criteria for adverse events

    Measured: first treatment day to death up to 33 Months

  7. CELsignia score and Objective Response

    The correlation between quantitative CELsignia score and OR, will be assessed to evaluate different cut-off values and corresponding treatment responses. CELsignia HER2 Pathway Activity Test

    Measured: Up to 33 Months

  8. CELsignia score and CB

    The correlation between quantitative CELsignia score and CB, will be assessed to evaluate different cut-off values and corresponding treatment responses. (CELsignia HER2 Pathway Activity Test)

    Measured: Up to 33 Months

  9. CELsignia score and Progression Free Survival

    The correlation between quantitative CELsignia score and PFS, will be assessed to evaluate different cut-off values and corresponding treatment responses. (CELsignia HER2 Pathway Activity Test)

    Measured: up to 33 months

  10. CELsignia score and molecular alterations in plasma

    The correlation between quantitative CELsignia score and molecular alterations in plasma, particularly HER2 mutations. ( CELsignia HER2 Pathway Activity Test)

    Measured: Up to 33 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 May 2021
  2. Study startJul 2023 (estimated)
  3. Primary completion1 Jul 2024 (estimated)
  4. Study completion1 Jul 2025 (estimated)

Why it stopped: Team decision

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04901299
Sponsor's protocol ID
21-038
Acronym
HER2-Signal
Status last verified
Jul 2023
First submitted
18 May 2021
Last updated
1 Aug 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing NERATINIB and FULVESTRANT in people with Stage IV (Metastatic) Breast Cancer and Metastatic Breast Cancer, run by Massachusetts General Hospital at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 1 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective response rates (ORR) (time frame: Up to 33 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04901299.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in